ALX Oncology Holdings (NAS:ALXO) Net Intangibles Purchase And Sale

: $0.00 Mil (TTM As of Dec. 2022)

View and export this data going back to 2020. Start your Free Trial

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

ALX Oncology Holdings's net Intangibles purchase and sale for the three months ended in Dec. 2022 was $0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

ALX Oncology Holdings Net Intangibles Purchase And Sale Historical Data

The historical data trend for ALX Oncology Holdings's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Net Intangibles Purchase And Sale

-4.26

ALX Oncology Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Net Intangibles Purchase And Sale													-	-	-	-	-

ALX Oncology Holdings Net Intangibles Purchase And Sale Calculation

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

ALX Oncology Holdings Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

ALX Oncology Holdings (NAS:ALXO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » Net Intangibles Purchase And Sale

Comparable Companies

Traded in Other Exchanges

N/A

Address

323 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alxoncology.com

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Executives

J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas	director	C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Shelly Pinto	officer: VP, Finance and CAO	866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Michael A Carusi	10 percent owner	1000 WINTER STREET, SUITE 3700, WALTHAM MA 02451
Venbio Global Strategic Gp Ii, Ltd.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Plain Henry A Jr	10 percent owner	125 CONSTITUTION DRIVE, MENLO PARK CA 94025-1118
Lightstone Ventures, L.p.	10 percent owner	500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Lightstone Ventures (a), L.p.	10 percent owner	500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Lsv Associates, Llc	10 percent owner	2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
Jason Lettmann	director, 10 percent owner	C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Lightstone Ventures Ii, L.p.	10 percent owner	500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Lightstone Ventures Ii (a), L.p.	10 percent owner	500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Jaume Pons	director, officer: President and CEO	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010